Bupropion (Wellbutrin) Clinical Guide
Bupropion is an effective antidepressant and smoking cessation agent with a unique dopamine-norepinephrine mechanism, requiring careful dosing titration and strict contraindication screening to minimize seizure risk.
Indications
Bupropion is FDA-approved for:
- Major depressive disorder (all formulations)
- Smoking cessation (sustained-release formulation as Zyban) 1
- Seasonal affective disorder 2
Off-label uses include ADHD (though evidence is limited) 3 and as a component of naltrexone-bupropion ER for obesity management 4.
Dosing Guidelines
For Smoking Cessation (NCCN Guidelines)
Standard protocol 1:
- Initiate 1-2 weeks prior to quit date
- Days 1-3: 150 mg orally once daily
- Day 4 through 12 weeks: 150 mg orally twice daily (if tolerated)
- Maximum: 300 mg per day
- Duration: 7-12 weeks (may extend to 6 months-1 year for continued cessation)
For Depression
- Immediate-release: Start 150 mg daily, titrate to 300-450 mg/day in divided doses (maximum 450 mg/day) 5, 6
- Sustained-release: 150 mg twice daily (maximum 400 mg/day) 6
- Extended-release: 150-300 mg once daily (maximum 450 mg/day) 6
Critical dosing consideration: Gradual titration is mandatory to minimize seizure risk 5, 7.
Absolute Contraindications (FDA Label)
Do not prescribe bupropion if the patient has 8:
- Seizure disorder (current or history)
- Current or prior bulimia or anorexia nervosa (higher seizure incidence)
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
- Brain metastases or stroke (increased seizure risk) 1
- MAOI use within 14 days (hypertensive crisis risk) 1, 8
- Concurrent tamoxifen use 1
- Closed-angle glaucoma 1
- Known hypersensitivity to bupropion 8
Side Effects
Common (Generally Well-Tolerated)
- Insomnia and nervousness (most common) 2, 9
- Dry mouth 5, 7
- Headache 9
- Nausea 9
- Agitation 5
- Constipation 5
Key advantage: Significantly less sexual dysfunction compared to SSRIs 10, 6 and less somnolence and weight gain than tricyclic antidepressants 6.
Serious Adverse Effects (Rare)
Seizures: Risk is approximately 1 in 1,000 at therapeutic doses 11, 7, 9. This risk is comparable to other antidepressants when dosing guidelines are followed 7.
Neuropsychiatric effects: Although historically concerning, a large multicenter RCT (EAGLES trial, n=8,058) found that neuropsychiatric adverse events with bupropion were not significantly increased compared to nicotine patches or placebo in patients with or without psychiatric disorders 1. However, the FDA still advises monitoring for depression, suicidal ideation/behavior, hostility, and agitation 1.
Hypersensitivity reactions: Risk of 1 in 1,000 to 1 in 10,000, including serum sickness-like reactions 11, 9.
Monitoring Recommendations
Initial Assessment
Screen for:
- History of seizures or conditions lowering seizure threshold
- Eating disorders (bulimia, anorexia)
- Current alcohol or benzodiazepine use
- Psychiatric history (though not a contraindication)
- Concurrent medications (MAOIs, CYP2D6 substrates)
Ongoing Monitoring
For depression treatment 10:
- Begin monitoring within 1-2 weeks of initiation
- Assess for suicidal thoughts/behaviors, agitation, irritability, unusual behavioral changes
- Risk for suicide attempts is greatest during first 1-2 months
- Evaluate therapeutic response at 6-8 weeks; modify treatment if inadequate response
For smoking cessation 1:
- Monitor for neuropsychiatric symptoms (depression, suicidal ideation)
- Track smoking reduction progress
- If reduction stalls or abstinence seems unlikely, consider switching pharmacotherapy
For all indications:
- Monitor blood pressure (can increase BP) 4
- Assess for seizure activity
- Evaluate tolerability and adherence
Special Populations
Renal impairment: Reduce dose by 50% in moderate-to-severe impairment; avoid in end-stage renal disease 4.
Hepatic impairment: Maximum 150 mg daily in moderate-to-severe impairment 4.
Pregnancy: Likely safer than continued smoking, though data limited 11.
Adolescents (10-18 years): Recent ATS guidelines suggest a trial of bupropion for nicotine cessation despite very low-quality evidence, based on potential benefits outweighing risks 12.
Drug Interactions
- MAOIs: Absolute contraindication; 14-day washout required 8
- CYP2D6 substrates: Bupropion inhibits CYP2D6, raising concern for interactions 2
- Medications lowering seizure threshold: Use extreme caution 9
- Tamoxifen: Contraindicated 1
Clinical Pearls
When to prioritize bupropion:
- Patients with depression and smoking cessation goals (dual benefit) 4, 2
- Patients who cannot tolerate SSRI sexual side effects 10, 6
- Patients concerned about weight gain with antidepressants 6
- Patients with comorbid depression and obesity (as naltrexone-bupropion ER) 4
Common pitfall: Prescribing to patients with unrecognized eating disorders or seizure risk factors. Always screen thoroughly before initiating 8.
Efficacy timeline: Onset of antidepressant action is typically 2 weeks, with full efficacy at 4 weeks 5. For smoking cessation, initiate 1-2 weeks before quit date 1.